Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Field Trip

Ketamine clinics have emerged across the US. They’re already going bust

The industry touting the drug as an antidepressant has grown too quickly, experts say, leaving patients at risk

The Guardian - US

Laid off workers can now get a free month of ketamine assisted therapy services to help with their mental health

Laid off workers can now get a free month of ketamine assisted therapy services to help with their mental health

The free service from Field Trip Health is open to "anyone who's facing headwinds right now."

Psychedelics Stream: New Platforms And Apps Providing Up-To-Date Info & Resources

Psychedelics Stream: New Platforms And Apps Providing Up-To-Date Info & Resources

The growing acceptance of psychedelics as a source for treating health conditions and promoting wellbeing has led several companies and non-profit organizations worldwide to launch initiatives supporting those interested in accessing these therapies, ranging from programs on

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed

Field Trip (NASDAQ: FTRP), Wesana (OTCQB: WSNAF), Braxia (OTC: BRAXF) and

Former Field Trip Health, Now Reunion Neuroscience: Q1 2023 Financial Results & Corporate Reorganization

Field Trip Discovery and Field Trip Health have been reorganized into two separate companies. The Discovery division has been renamed Reunion Neuroscience Inc. and may be found on NASDAQ and CSE as “REUN”, while Field Trip Health is now Field Trip Health & Wellness Ltd.

Field Trip's Phase I Clinical Study Of Psilocybin Analog FT-104 Begins Dosing In Australia

Developer and provider of psychedelic therapies Field Trip Health Ltd. has announced the first successful dosing of a Phase 1 clinical trial on it's proprietary psychedelic molecule.

Field Trip Shares Fiscal Q4 And Full Year 2022 Results & Update On Court-Approved Corporate Reorganization

Psychedelic therapies developer and provider Field Trip Health Ltd.

inkl

Read news from The Economist, FT, and more,
with one subscription

Field Trip Launches At-Home Ketamine Treatment In Partnership With Nue Life

Field Trip Launches At-Home Ketamine Treatment In Partnership With Nue Life

Field Trip Health (NASDAQ: FTRP), a company offering mental health treatment using ketamine therapy, has inked a unique deal with Nue Life Health to expand its service offerings to at-home treatment.

Field Trip Health To Divide Into Two Separate Public Companies

Field Trip Health To Divide Into Two Separate Public Companies

Field Trip Health (NASDAQ: FTRP) will divide two of its divisions into public companies of their own.

These 3 Psychedelic Stocks Will Benefit When The FDA Green-Lights MDMA (Molly, Ecstasy)

What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted therapy.

Nasdaq-Listed Field Trip Gets First Patent Approved For Improved Psychedelic Drug

Nasdaq-Listed Field Trip Gets First Patent Approved For Improved Psychedelic Drug

Field Trip Health Ltd. (NASDAQ:FTRP), a biotech and care delivery company in the psychedelics space, has been granted its first patent by the U.S. Patent and Trademark Office. The patent covers claims around FT-104, the company’s flagship proprietary psychedelic molecule, for composition of matter, use and manufacturing of the compound…

Five Companies Developing Second Generation Psychedelics For Mental Health

Five Companies Developing Second Generation Psychedelics For Mental Health

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second generation psychedelics could be the key to success in an increasingly…

Psyched: First Australian Psych Company On Nasdaq, Utah's Psychedelics Bill, LSD Vs. Psilocybin Study Unprecedented Results

Psyched: First Australian Psych Company On Nasdaq, Utah's Psychedelics Bill, LSD Vs. Psilocybin Study Unprecedented Results

On the legislative front of the psychedelics space, a new bill meant to study the therapeutic effects of psychedelic substances received full approval in both Utah chambers, standing out from among dozens of measures currently circulating in legislatures across several U.S. states. Psychedelic science also took an important step forward with the publication…

Field Trip And Cerebral Partner To Bring Together Teletherapy, Telepsychiatry, And Psychedelic-Assisted Therapy

Field Trip And Cerebral Partner To Bring Together Teletherapy, Telepsychiatry, And Psychedelic-Assisted Therapy

Field Trip Health Ltd. (NASDAQ:FTRP) (TSX:FTRP) and Cerebral are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health's ketamine assisted therapy, while Field Trip will connect potential clients seeking general psychiatry and teletherapy services to Cerebral. This end-to-end solution will provide personalized treatment solutions for…

Get all your
news in one place.

100's of premium titles.
One news app.

Field Trip Health Posts 330% YoY Increase In Q3 Revenue

Psychedelics company Field Trip Health Ltd. (TSX: FTRP) (NASDAQ: FTRP) reported its third fiscal quarter 2022 results for the three months ended December 31, 2021 and provided a business update.

Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event

Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15.

Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Monash University

Johns Hopkins University

Field Trip Health

Psychedelic Spotlight

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

359,066 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play